PSP Research’s Upstream Bio Inc UPB Stock Holding History

PSP Research’s Portfolio UPB Stock Details UPB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-17,634	Closed	-$479K	–	103
2025 Q4	$479K	Buy	+17,634	New	+$439K	0.42%	78

Other funds holding UPB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

PSP Research's UPB Position: Q1 2026 in Review

PSP Research sold out of Upstream Bio Inc (UPB) in Q1 2026, closing a stake of 17,634 shares — an estimated $479K sold.

PSP Research first reported a position in UPB in Q4 2025 and held it in 1 quarter. The position peaked at $479K in Q4 2025. 140 funds tracked by Wall St. Rank hold UPB as of Q1 2026.

PSP Research reported no remaining Upstream Bio Inc position as of Q1 2026 after selling out during the quarter.
PSP Research sold 17,634 Upstream Bio Inc shares in Q1 2026, an estimated $479K.
PSP Research first reported a position in Upstream Bio Inc in Q4 2025 and held it in 1 quarter.
PSP Research's Upstream Bio Inc position peaked at $479K in Q4 2025.
140 funds tracked by Wall St. Rank held Upstream Bio Inc as of Q1 2026.

Based on PSP Research's 13F filing for Q1 2026, filed 17 Apr 2026.